Commercializing diarrhea vaccines for travelers

References

• World Tourism Organization. International tourism receipts grew by 4% in 2012. PR 13033. World Tourism Organization (UNWTO) 2013; Capitán Haya 42, 28020 Madrid, Spain. http://media.unwto.org/en/press-release/2013-05-15/international-tourism-receipts-grew-4-2012
   Google Scholar
• Hay SI, Battle KE, Pigott DM, Smith DL, Moyes CL, Bhatt S, Brownstein JS, Collier N, Myers MF, George DB, et al. Global mapping of infectious disease. Philos Trans R Soc Lond B Biol Sci 2013; 368:20120250; http://dx.doi.org/10.1098/rstb.2012.0250; PMID: 23382431
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diarrohoeal disease. Fact Sheet nº 330. April 2013; Geneva: World Health Organization. http://www.who.int/mediacentre/factsheets/fs330/en/index.html
   Google Scholar
• World Health Organization. International Travel and Health. Situation as on 1 January 2012. WHO Press, 2013; Geneva: World Health Organization.
   Google Scholar
• World Health Organization. Preventing travellers' diarrhoea: How to make drinking water safe. In: Susteinable Development and Healthy Environments Water, Sanitation and Health. 2005; Geneva: World Health Organization. http://www.who.int/water_sanitation_health/hygiene/envsan/sdwtravel.pdf
   Google Scholar
• World Health Organization. Initiative for vaccine research (IVR) diarrhoeal diseases. Updated February 2009; Accessed 2013; Geneva: World Health Organization. http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index.html
   Google Scholar
• Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis 2004; 17:461 - 9; http://dx.doi.org/10.1097/00001432-200410000-00011; PMID: 15353966
   PubMed Web of Science ®Google Scholar
• Connor BA. Chapter 2. Travelers' diarrhea. In: CDC Health Information for International Travel 2014 (Yellow Book). 2014th ed. 2013; Oxford University Press. USA.
   Google Scholar
• World Health Organization. Cholera. Fact Sheet N°107. 2009; Geneva: World Health Organization. http://www.who.int/mediacentre/factsheets/fs107/en/
   Google Scholar
• World Health Organization. Cholera, 2012. Wkly Epidemiol Rec 2013; 88:321 - 34; PMID: 23980290
   PubMedGoogle Scholar
• Gascón J. Epidemiology, etiology and pathophysiology of traveler’s diarrhea. Digestion 2006; 73:Suppl 1 102 - 8; http://dx.doi.org/10.1159/000089785; PMID: 16498258
   PubMedGoogle Scholar
• Wang M, Szucs TD, Steffen R. Economic aspects of travelers’ diarrhea. J Travel Med 2008; 15:110 - 8; http://dx.doi.org/10.1111/j.1708-8305.2008.00189.x; PMID: 18346244
   PubMed Web of Science ®Google Scholar
• Torrell JMR, Aumatell CM, Ramos SM, Mestre LG, Salas CM. Reduction of travellers’ diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers. Vaccine 2009; 27:4074 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.04.025; PMID: 19376179
   PubMed Web of Science ®Google Scholar
• López-Gigosos R, Campins M, Calvo MJ, Pérez-Hoyos S, Díez-Domingo J, Salleras L, Azuara MT, Martínez X, Bayas JM, Ramón Torrell JM, et al. Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler’s diarrhea: A prospective cohort study. Hum Vaccin Immunother 2013; 9:692 - 8; http://dx.doi.org/10.4161/hv.23267; PMID: 23324573
   PubMed Web of Science ®Google Scholar
• Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346 - 53; PMID: 15298225
   PubMed Web of Science ®Google Scholar
• Steele D. The importance of generating evidence on typhoid fever for implementing vaccination strategies. J Infect Dev Ctries 2008; 2:250 - 2; http://dx.doi.org/10.3855/jidc.217; PMID: 19741284
   PubMed Web of Science ®Google Scholar
• Breiman RF, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng JB, Wamola N, Bigogo GM, Awiti G, Tabu CW, et al. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. PLoS One 2012; 7:e29119; http://dx.doi.org/10.1371/journal.pone.0029119; PMID: 22276105
   PubMed Web of Science ®Google Scholar
• Alliance GAVI. Vaccine Investment Strategy: Typhoid analysis documentation vaccine investment strategy 2013; GAVI Alliance Secretariat. Geneva, Switzerland. http://www.gavialliance.org/about/strategy/vaccine-investment-strategy/
   Google Scholar
• Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005; 366:749 - 62; http://dx.doi.org/10.1016/S0140-6736(05)67181-4; PMID: 16125594
   PubMed Web of Science ®Google Scholar
• Fangtham M, Wilde H. Emergence of Salmonella paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines. J Travel Med 2008; 15:344 - 50; http://dx.doi.org/10.1111/j.1708-8305.2008.00237.x; PMID: 19006508
   PubMed Web of Science ®Google Scholar
• Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TTT, Van Vinh Chau N, Tuan PQ, Page AL, Ochiai RL, et al. Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007; 51:4315 - 23; http://dx.doi.org/10.1128/AAC.00294-07; PMID: 17908946
   PubMed Web of Science ®Google Scholar
• Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, Ackers M, Calugar A, Mintz ED. Typhoid fever in travelers: who should be targeted for prevention?. Clin Infect Dis 2004; 39:186 - 91; http://dx.doi.org/10.1086/421945; PMID: 15307027
   PubMed Web of Science ®Google Scholar
• Tacket CO, Ferreccio C, Robbins JB, Tsai CM, Schulz D, Cadoz M, Goudeau A, Levine MM. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986; 154:342 - 5; http://dx.doi.org/10.1093/infdis/154.2.342; PMID: 2425009
   PubMed Web of Science ®Google Scholar
• Azze RFO, Rodríguez JCM, Iniesta MG, Marchena XRF, Alfonso VMR, Padrón FTS. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers. Vaccine 2003; 21:2758 - 60; http://dx.doi.org/10.1016/S0264-410X(03)00177-4; PMID: 12798615
   PubMed Web of Science ®Google Scholar
• Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12:195 - 9; http://dx.doi.org/10.1016/0264-410X(94)90194-5; PMID: 8165850
   PubMed Web of Science ®Google Scholar
• Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin Dev Immunol 2008; 2008:628963; http://dx.doi.org/10.1155/2008/628963; PMID: 18825269
   PubMed Web of Science ®Google Scholar
• Ohtake S, Martin R, Saxena A, Pham B, Chiueh G, Osorio M, Kopecko D, Xu D, Lechuga-Ballesteros D, Truong-Le V. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 2011; 29:2761 - 71; http://dx.doi.org/10.1016/j.vaccine.2011.01.093; PMID: 21300096
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17:Suppl 2 S22 - 7; http://dx.doi.org/10.1016/S0264-410X(99)00231-5; PMID: 10506405
   PubMed Web of Science ®Google Scholar
• Salerno-Gonçalves R, Wahid R, Sztein MB. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect Immun 2005; 73:3521 - 30; http://dx.doi.org/10.1128/IAI.73.6.3521-3530.2005; PMID: 15908381
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11:Suppl 3 S552 - 67; http://dx.doi.org/10.1093/clinids/11.Supplement_3.S552; PMID: 2669099
   PubMedGoogle Scholar
• Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine 1990; 8:81 - 4; http://dx.doi.org/10.1016/0264-410X(90)90183-M; PMID: 2180234
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007; 45:Suppl 1 S24 - 8; http://dx.doi.org/10.1086/518141; PMID: 17582564
   PubMed Web of Science ®Google Scholar
• Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012; 19:825 - 34; http://dx.doi.org/10.1128/CVI.00058-12; PMID: 22492745
   PubMed Web of Science ®Google Scholar
• Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, Lell B, Que JU, Miller GB, Kremsner PG. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35:1147 - 54; http://dx.doi.org/10.1086/342908; PMID: 12410473
   PubMed Web of Science ®Google Scholar
• Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009; 16:46 - 52; http://dx.doi.org/10.1111/j.1708-8305.2008.00273.x; PMID: 19192128
   PubMed Web of Science ®Google Scholar
• Garg SP. Vi conjugate typhoid vaccine. Indian Pediatr 2009; 46:736 - 7; PMID: 19717873
   PubMed Web of Science ®Google Scholar
• Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers’ diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009; 80:609 - 14; PMID: 19346386
   PubMed Web of Science ®Google Scholar
• Chinnasami B, Mangayarkarasi V, Prema A, Sadasivam K, Davis M. Safety and immunogenicity of Salmonella Typhy vi conjugate vaccine (peda TyphTM) in children up to five years. Int J Sci Res Pub 2013; 3:1 - 5
   Google Scholar
• World Health Organization. The immunological basis for immunization serie S. Module 18. hepatitis A. In: World Health Organization, ed. Immunization, Vaccines and Biologicals. WHO Library Cataloguing-in-Publication Data 2011; Geneva: World Health Organization. http://www.who.int/immunization/documents/immunological_basis_series/en/
   Google Scholar
• Plotkin S, Orenstein W, Offit P. Vaccines. 6th Edition ed. Elsevier Inc.; 2013. USA.
   Google Scholar
• World Health Organization. WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec 2012; 87:261 - 76; PMID: 22905367
   PubMedGoogle Scholar
• Hendrickx G, Vorsters A, Van Damme P. Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery. Curr Opin Infect Dis 2012; 25:578 - 83; http://dx.doi.org/10.1097/QCO.0b013e328357e65c; PMID: 22907280
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, Loutan L. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010; 82:1629 - 34; http://dx.doi.org/10.1002/jmv.21883; PMID: 20827757
   PubMed Web of Science ®Google Scholar
• Zheng H, Chen Y, Wang F, Gong X, Wu Z, Miao N, Zhang X, Li H, Chen C, Hou X, et al. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose. Vaccine 2011; 29:9098 - 103; http://dx.doi.org/10.1016/j.vaccine.2011.08.078; PMID: 21875638
   PubMed Web of Science ®Google Scholar
• Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine 2012; 31:3 - 11; http://dx.doi.org/10.1016/j.vaccine.2012.04.104; PMID: 22609026
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2009) International travel and health. Situation as on 1 January 2009. Geneva: World Health Organization.
   Google Scholar
• Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, Masson P, De Keyser F. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49:1815 - 27; http://dx.doi.org/10.1093/rheumatology/keq183; PMID: 20591834
   PubMed Web of Science ®Google Scholar
• Gelinck LBS, Kroon FP. Vaccination of HIV-infected adults. HIV Therapy 2009; 3:565 - 72; http://dx.doi.org/10.2217/hiv.09.39
   Google Scholar
• Sharapov U, Teshale E. Chapter 3. Infectious diseases related to travel. Hepatitis A. In: CDC Health Information for International Travel (Yellow Book). 2014th ed. 2013; Oxford University Press. USA.
   Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. Pediatrics 2011; 128:803 - 4; http://dx.doi.org/10.1542/peds.2011-1495; PMID: 21949136
   PubMed Web of Science ®Google Scholar
• Connor BA. Hepatitis A vaccine in the last-minute traveler. Am J Med 2005; 118:Suppl 10A 58S - 62S; http://dx.doi.org/10.1016/j.amjmed.2005.07.018; PMID: 16271543
   PubMedGoogle Scholar
• Public Health Agency Canada. Statement on hepatitis vaccines for travellers. Vol 34, ACS-2 july 2008. Accesed 2013; Canada. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/08vol34/acs-2/index-eng.php
   Google Scholar
• Abarca K, Ibáñez I, de la Fuente P, Cerda L, Bergeret J, Frösner G, Ibarra H. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years. Vaccine 2011; 29:8855 - 62; http://dx.doi.org/10.1016/j.vaccine.2011.09.095; PMID: 21983354
   PubMed Web of Science ®Google Scholar
• Keystone J. In. Travel Medicine. 3th edition ed. Elsevier; 2013; USA
   Google Scholar
• European Medicine Agency. Twinrix paediatric-H-C-129-P45-42: EPAR - assessment report. GlaxoSmithKline. Accessed 2013; London. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000129/human_med_001117.jsp&mid=WC0b01ac058001d124
   Google Scholar
• European Medicine Agency. Twinrix adult, suspension for injection hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed). GlaxoSmithKline. Accessed 2013; London. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000112/WC500044064.pdf
   Google Scholar
• Public Health Agency Canada. Canadian immunization guide. Part 4. Typhoid vaccine. 2013; Canada. http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-typh-eng.php
   Google Scholar
• Rodríguez-Frias F, Jardi R, Buti M. [Hepatitis E: molecular virology, epidemiology and pathogenesis]. Enferm Infecc Microbiol Clin 2012; 30:624 - 34; http://dx.doi.org/10.1016/j.eimc.2012.01.014; PMID: 22386306
   PubMed Web of Science ®Google Scholar
• Thomson K, Dvorzak JL, Lagu J, Laku R, Dineen B, Schilperoord M, Muita M, Gikunju S, Waiboci L, Fields B, et al, Centers for Disease Control and Prevention (CDC). Investigation of hepatitis E outbreak among refugees - Upper Nile, South Sudan, 2012-2013. MMWR Morb Mortal Wkly Rep 2013; 62:581 - 6; PMID: 23884344
   PubMed Web of Science ®Google Scholar
• Park SB. Hepatitis E vaccine debuts. Nature 2012; 491:21 - 2; http://dx.doi.org/10.1038/491021a; PMID: 23128204
   PubMed Web of Science ®Google Scholar
• Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q. Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 2012; 8:823 - 7; http://dx.doi.org/10.4161/hv.20042; PMID: 22699438
   PubMed Web of Science ®Google Scholar
• World Health Organization. Call for nominations for SAGE working group on hepatitis E vaccine. 2013; Geneva: World Health Organization. http://www.who.int/immunization/sage/nominations_working_group_hep_E_aug2013/en/index.html
   Google Scholar
• Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895 - 902; http://dx.doi.org/10.1016/S0140-6736(10)61030-6; PMID: 20728932
   PubMed Web of Science ®Google Scholar
• Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers’ diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009; 80:609 - 14; PMID: 19346386
   PubMed Web of Science ®Google Scholar
• Glass RI, Noel J, Ando T, Fankhauser R, Belliot G, Mounts A, Parashar UD, Bresee JS, Monroe SS. The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J Infect Dis 2000; 181:Suppl 2 S254 - 61; http://dx.doi.org/10.1086/315588; PMID: 10804134
   PubMed Web of Science ®Google Scholar
• Löscher M, Alberer M. Chapter 20. Clinical presentation and management of travelers' diarrhea. In: Keystone JS, ed. Travel Medicine. 3rd Edition ed. USA: Elsevier Inc; 2013.
   Google Scholar
• World Health Organization. Rotavirus vaccines. WHO position paper. Week Epidem Rec 2013; 88:49-64. http://www.who.int/immunization/topics/rotavirus/en/index.html
   Google Scholar
• Sahni L, Boom J. Commentary on “Vaccines for preventing rotavirus: Vaccines in use”. Evid Based Child Health 2011; 6:757 - 758; http://dx.doi.org/10.1002/ebch.721
   Google Scholar
• World Health Organization. Fact sheet nº 378. Immunization coverage. Updater November 2013; Geneva, World Health Organization. http://centerforvaccineethicsandpolicy.net/2013/11/03/who-immunization-coverage-fact-sheet-n378-updated-november-2013/
   Google Scholar
• Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: Vaccines in use. Cochrane Summaries Published Online: November 14, 2012; http://summaries.cochrane.org/CD008521/vaccines-for-preventing-rotavirus-diarrhoea-vaccines-in-use
   Google Scholar